Renal Osteodystrophy in the First Decade of the New Millennium: Analysis of 630 Bone Biopsies in Black and White Patients

被引:253
作者
Malluche, Hartmut H. [1 ]
Mawad, Hanna W. [1 ]
Monier-Faugere, Marie-Claude [1 ]
机构
[1] Univ Kentucky, Med Ctr, Div Nephrol Bone & Mineral Metab, Lexington, KY 40536 USA
关键词
RENAL OSTEODYSTROPHY; BONE HISTOMORPHOMETRY; BONE TURNOVER; MINERALIZATION; BONE VOLUME; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; PARATHYROID-HORMONE; LANTHANUM CARBONATE; BIOCHEMICAL MARKERS; DIALYSIS PATIENTS; COMPACT-BONE; VITAMIN-D; FRACTURES; HISTOMORPHOMETRY;
D O I
10.1002/jbmr.309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal osteodystrophy occurs early during loss of kidney function. There are 26 million American patients with chronic kidney disease (CKD), and almost all patients with CKD stage 5 have abnormal bone histology. Six hundred and thirty bone biopsies from adult CKD-5 patients on dialysis were evaluated by histomorphometry and analyzed using the turnover (T), mineralization (M), and volume (V) classification. There were racial differences; whites exhibited predominantly low turnover (62%), whereas blacks showed mostly normal or high turnover (68%). A mineralization defect was observed in only 3% of patients. In whites, cancellous bone volume was low, normal, or high in approximately the same number of patients, whereas in blacks, cancellous bone volume was high in two-thirds of the patients. More than 80% of blacks and whites with low cancellous bone volume had thin trabeculae owing to low bone formation. Cortical thickness was low in half the whites, whereas it was normal in three-quarters of blacks. Cortical porosity was high in 50% of whites, whereas three-quarters of blacks had high porosity. In summary, the TMV system gives relevant information. It should be expanded to include the architecture of cancellous and cortical bone. There are racial differences. Low bone volume and low bone turnover are more frequent than heretofore appreciated, whereas mineralization defects nowadays are observed rarely in adults. These findings call for an adjustment of the current therapeutic paradigm that takes into consideration race and risk of low bone volume and turnover. The latter have been shown to be associated with increased vascular calcifications. (C) 2011 American Society for Bone and Mineral Research.
引用
收藏
页码:1368 / 1376
页数:9
相关论文
共 44 条
[1]   Low Bone Volume-A Risk Factor for Coronary Calcifications in Hemodialysis Patients [J].
Adragao, Teresa ;
Herberth, Johann ;
Monier-Faugere, Marie-Claude ;
Branscum, Adam J. ;
Ferreira, Anibal ;
Frazao, Joao M. ;
Curto, Jose Dias ;
Malluche, Hartmut H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02) :450-455
[2]   Risk factors for vertebral fractures in renal osteodystrophy [J].
Atsumi, K ;
Kushida, K ;
Yamazaki, K ;
Shimizu, S ;
Ohmura, A ;
Inoue, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) :287-293
[3]  
Bakkaloglu SA, 2010, CLIN J AM SOC NEPHRO
[4]  
BORDIER P, 1978, J CLIN ENDOCR METAB, V46, P284, DOI 10.1210/jcem-46-2-284
[5]   Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions [J].
Cantor, Tom ;
Yang, Zan ;
Caraiani, Nicolae ;
Ilamathi, Ekambaram .
CLINICAL CHEMISTRY, 2006, 52 (09) :1771-1776
[6]   Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone [J].
Coco, M ;
Rush, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (06) :1115-1121
[7]   Prevalence of chronic kidney disease in the United States [J].
Coresh, Josef ;
Selvin, Elizabeth ;
Stevens, Lesley A. ;
Manzi, Jane ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Levey, Andrew S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (17) :2038-2047
[8]   Low bone turnover in patients with renal failure [J].
Couttenye, MM ;
D'Haese, PC ;
Verschoren, WJ ;
Behets, GJ ;
Schrooten, I ;
De Broe, ME .
KIDNEY INTERNATIONAL, 1999, 56 :S70-S76
[10]   A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients [J].
D'Haese, PC ;
Spasovski, GB ;
Sikole, A ;
Hutchison, A ;
Freemont, TJ ;
Sulkova, S ;
Swanepoel, C ;
Pejanovic, S ;
Djukanovic, L ;
Balducci, A ;
Coen, G ;
Sulowicz, W ;
Ferreira, A ;
Torres, A ;
Curic, S ;
Popovic, M ;
Dimkovic, N ;
De Broe, ME .
KIDNEY INTERNATIONAL, 2003, 63 :S73-S78